Philippines

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection
  • July 11th, 2014
  • A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

» Read More...
Featured Research »
Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

Health & Medicine »
Heart Failure Hits Asians Earlier

Heart Failure Hits Asians Earlier

A study of 8,000 heart failure patients shows that heart failure occurs at a much younger age for Asians, who develop the disease a good decade before people in Western countries.

Academia »
Researcher Awarded For The Magic Glasses Cartoon

Researcher Awarded For The Magic Glasses Cartoon

A cartoon that has helped halve parasitic worm infection rates among rural Chinese children has earned a University of Queensland researcher a prestigious award.

Tech & Pharma »
Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

The Phase III trial, which enrolled more than 10,000 children in Asia, showed that vaccination led to a 56 percent reduction in dengue cases.

Editorials »
Bridging The ASEAN Research Gap

Bridging The ASEAN Research Gap

Research and innovation in ASEAN has not kept pace with economic growth the region has enjoyed, writes Crispin Maslog.